Thermo Fisher Scientific delivered a strong second quarter in 2025, with revenue increasing by 3% to $10.85 billion and GAAP diluted EPS growing by 6% to $4.28. The company demonstrated excellent operational performance, driven by its PPI Business System, and continued to advance its growth strategy through innovation and strategic partnerships, despite a slight dip in adjusted EPS.
Second quarter revenue increased by 3% to $10.85 billion, up from $10.54 billion in the prior year.
GAAP diluted EPS grew by 6% to $4.28, compared to $4.04 in the second quarter of 2024.
Adjusted EPS was $5.36, a slight decrease from $5.37 in the same period last year.
The company achieved 2% organic revenue growth, reflecting strong operational execution and market share gains.
The company will provide updated 2025 financial guidance during its earnings conference call.
Analyze how earnings announcements historically affect stock price performance